Company: TBPH
Filing Date: 2025-08-25
Form Type: 8-K
Source: 0001104659-25-082048
Chunk: 0

Company: Theravance Biopharma, Inc.
Filing Date: 2025-08-25
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

On August 25, 2025, Theravance Biopharma, Inc. (NASDAQ: TBPH)
announced that it completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic
orthostatic hypotension (nOH) due to multiple system atrophy (MSA).

A copy of the press release is furnished as Exhibit 99.1 to this
Current Report.

The information in this Current Report (including Exhibit 99.1)
is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1)
shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

  99.1      Press Release dated August 25, 2025                                        
 ───────────────────────────────────────────────────────────────────────────────────────
   104      Cover Page Interactive                                                     

SIGNATURE

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                             THERAVANCE BIOPHARMA, INC.                                                         
  Date: August 25, 2025      By:                             /s/ Aziz Sawaf                                     
                                                             Aziz Sawaf                                         
                                                             Senior Vice President and Chief Financial Officer